Kenneth J. Bloom, M.D.

Kenneth J. Bloom, M.D., has been Medical Director at Clarient since August 2004. Previously, Dr. Bloom served as Senior Medical Director at Irvine, CA-based US LABS. Prior to that, Dr. Bloom spent more than 2 decades serving in senior academic, consultative, and clinical roles with leading hospitals and healthcare enterprises principally in the specialization of cancer care.

Dr. Bloom's academic posts have included 10 years as Assistant Professor of Pathology and 2 years as Associate Professor of Pathology at Chicago-based Rush Medical College, as well as 1 year as a visiting Professor in the Department of Computer Science at DePaul University. Over the past 15 years, Dr. Bloom has held more than 10 appointed positions at Chicago-based Rush Presbyterian–St. Luke's Medical Center, one of the leading cancer research hospitals in the United States. Those positions included Director of Laboratory Operations, Director of Immunohistochemistry, and Director of the Breast Service in the Department of Pathology, Consultant to the Rush Breast Cancer Center, and Director of Information Services for the Rush Cancer Institute.

For more than 3 decades, Dr. Bloom has been a prolific researcher and lecturer in the fields of pathology and, specifically, cancer-related topics. During his tenure at Rush, his published studies validating the benefits of ACIS® (Automated Cellular Imaging System) image analysis for Her2 evaluation were instrumental in gaining broad acceptance for the Clarient technology. He has been a member of the College of American Pathologists since 1987 and currently serves as a member of the Diagnostic Immunology Resource Committee for that organization.

In addition to US LABS and the other roles mentioned above, Dr. Bloom has served the industry off and on for the past 20 years in both advisory and operational roles. Those appointments include Board of Directors seats, consulting roles, and executive posts including executive-level positions at both diagnostics technology and information technology firms.